OncoBayes Advances OB-001 Development to Address ADC Resistance and TKI Brain Penetration

OncoBayes Advances the Development of OB-001

On October 7, 2026, OncoBayes, a privately held pharmaceutical company at the clinical stage, announced the successful completion of preclinical work on OB-001. This product has shown significant promise in addressing two critical unmet medical needs in oncology: antibody-drug conjugate (ADC) resistance and the brain penetration of tyrosine kinase inhibitors (TKIs).

The Mechanism Behind OB-001

OB-001 functions as a highly selective and effective inhibitor of two crucial efflux pumps, namely P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP), present at both the blood-brain barrier and on tumor cells. This innovative product is being developed as a once-daily oral tablet which can be used in conjunction with various standard oncology therapies to enhance their efficacy.

Preclinical studies conducted on mice with an intact blood-brain barrier demonstrated that treatment with OB-001 significantly elevated the concentrations of four established kinase inhibitors in the brain, while the systemic plasma concentrations remained largely unchanged. Notably, data presented at AACR 2026 indicated that OB-001 was able to increase the brain concentration of Osimertinib by nearly 400%, with minimal changes in systemic levels. This increase is expected to markedly improve progression-free survival in the central nervous system for patients with EGFR mutation-positive non-small cell lung cancer (EGFRm-NSCLC). This aspect of enhanced control of brain metastases continues to represent a critical area of unmet need in non-small cell lung cancer (NSCLC) and breast cancer treatment.

Addressing ADC Resistance

Additionally, the same efflux pumps have been identified as a key resistance mechanism that diminishes the effectiveness of ADCs, where their overexpression results in reduced drug concentration within the tumor. Preclinical investigations using a bidirectional transporter assay showed that OB-001 effectively reduces the efflux of several leading drugs, including SN-38 (e.g., Sacituzumab Govitecan, Trodelvy®), DM4 (e.g., Mirvetuximab Soravtansine, Elahere®), and DXd (e.g., Trastuzumab Deruxtecan, Enhertu®).

Currently, OncoBayes is preparing to transition toward a parallel clinical trial program aimed at obtaining proof-of-concept (POC) data in combination with Osimertinib and exploring the potential for resensitization via T-DXd.

The Future of OncoBayes

Jim Millen, the Chief Executive Officer of OncoBayes, stated, "This is a significant milestone for our team, and we are now well-positioned to initiate our clinical plans with OB-001. OB-001 is on track to become a first-in-class medication with substantial potential as a simple, orally administered adjunct to various successful oncology treatments. This represents a true product opportunity in our pipeline."

In conclusion, OB-001's promising results mark it as a beacon of hope in the ongoing battle against cancer, aiming to overcome existing treatment barriers such as ADC resistance and the challenge of effectively treating brain metastases. As preparations for clinical trials continue, the future for OB-001 appears bright, paving the way for improved patient outcomes in oncological therapies.